Non-M variants of human immunodeficiency virus type

Clinical Microbiology Reviews

Volumn 26, Issue 3, 2013, Pages 448-461

  Mourez, Thomas ^a,b,c   Simon, François ^d,e   Plantiera, Jean Christophe ^a,b,c  

^a NORMANDIE UNIVERSITÉ   (France)

^b UNIVERSITY OF ROUEN   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; GLYCOPROTEIN GP 120; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEF PROTEIN; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEIN VARIANT; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VPU PROTEIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTATION; ARTICLE; CHIMPANZEE; DISEASE COURSE; DISEASE SURVEILLANCE; EVOLUTION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; MOLECULAR EPIDEMIOLOGY; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PHYLOGENY; POLYMERASE CHAIN REACTION; SEROLOGY; SEROPREVALENCE; UNINDEXED SEQUENCE; VIRUS LOAD; VIRUS TRANSMISSION; WESTERN BLOTTING;

ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; PHYLOGENY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PAN; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84879759758     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00012-13     Document Type: Article

References (114)

1. Barré-Sinoussi F, Chermann JC, Rey P, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Brun-Vezinet F, Rouzioux C, Rozenbaum W, Montagnier L. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
2. Barin F, M'Boup S, Denis F, Kanki P, Allan JS, Lee TH, Essex M. 1985. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. Lancet ii:1387-1389.
3. Clavel F, Guétard D, Brun-Vézinet F, Chamaret S, Rey MA, Santos- Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, Klatzmann D, Champalimaud JL, Montagnier L. 1986. Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-346.
4. De Leys R, Vanderborght B, Vanden Haesevelde M, Heyndrickx L, van Geel A, Wauters C, Bernaerts R, Saman E, Nijs P, Willems B, Taelman H, van der Groen G, Piot P, Tersmette T, Huisman JG, van Heuverswyn H. 1990. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West- Central African origin. J. Virol. 64:1207-1216.
5. Nkengasong JN, Peeters M, vanden Haesevelde M, Musi SS, Willems B, Ndumbe PM, Delaporte E, Perret JL, Piot P, van den Groen G. 1993. Antigenic evidence of the presence of the aberrant HIV-1ant70 virus in Cameroon and Gabon. AIDS 7:1536-1538.
6. Gurtler LG, Hauser PH, Eberle J, von Brunn A, Knapp S, Zekeng L, Tsague JM, Kaptue L. 1994. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 68:1581-1585.
7. Charneau P, Borman AM, Quillent C, Guetard D, Chamaret S, Cohen J, Remy G, Montagnier L, Clavel F. 1994. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology 205:247-253.
8. Vanden Haesevelde M, Decourt JL, De Leys RJ, Vanderborght B, van der Groen G, van Heuverswijn H, Saman E. 1994. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J. Virol. 68:1586-1596.
9. Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barre-Sinoussi F, Brun- Vezinet F. 1998. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat. Med. 4:1032-1037.
10. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemee V, Damond F, Robertson DL, Simon F. 2009. A new human immunodeficiency virus derived from gorillas. Nat. Med. 15:871-872.
11. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, Loul S, Butel C, Liegeois F, Bienvenue Y, Ngolle EM, Sharp PM, Shaw GM, Delaporte E, Hahn BH, Peeters M. 2006. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 444:164. doi:10.1038 /444164a.
12. Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, Mbanya D, Kaptue L, Ndembi N, Gurtler L, Devare S, Brennan CA. 2011. Confirmation of putative HIV-1 group P in Cameroon. J. Virol. 85:1403-1407.
13. Peeters M, Honore C, Huet T, Bedjabaga L, Ossari S, Bussi P, Cooper RW, Delaporte E. 1989. Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon. AIDS 3:625-630.
14. Huet T, Cheynier R, Meyerhans A, Roelants G, Wain-Hobson S. 1990. Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature 345:356-359.
15. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436-441.
16. Hahn B, Shaw GM, De Cock K, Sharp PM. 2000. AIDS as a zoonosis: scientific and public health implications. Science 287:607-614.
17. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH. 2006. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523-526.
18. Van Heuverswyn F, Li Y, Bailes E, Neel C, Lafay B, Keele BF, Shaw KS, Takehisa J, Kraus MH, Loul S, Butel C, Liegeois F, Yangda B, Sharp PM, Mpoudi-Ngole E, Delaporte E, Hahn BH, Peeters M. 2007. Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology 368:155-171.
19. Takehisa J, Kraus MH, Ayouba A, Bailes E, Van Heuverswyn F, Decker JM, Li Y, Rudicell RS, Learn GH, Neel C, Ngole EM, Shaw GM, Peeters M, Sharp PM, Hahn BH. 2009. Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J. Virol. 83: 1635-1648.
20. Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, Muyembe JJ, Kabongo JM, Kalengayi RM, Van Marck E, Gilbert MT, Wolinsky SM. 2008. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 455:661-664.
21. Lemey P, Pybus OG, Rambaut A, Drummond AJ, Robertson DL, Roques P, Worobey M, Vandamme A-M. 2004. The molecular population genetics of HIV-1 group O. Genetics 167:1059-1068.
22. Wertheim JO, Worobey M. 2009. Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput. Biol. 5:e1000377. doi:10.1371/journal.pcbi.1000377.
23. Sauter D, Hue S, Petit SJ, Plantier JC, Towers GJ, Kirchhoff F, Gupta RK. 2011. HIV-1 group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology 8:103. doi:10.1186/1742-4690-8-103.
24. Jonassen TO, Stene-Johansen K, Berg ES, Hungnes O, Lindboe CF, Froland SS, Grinde B. 1997. Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s. Virology 231:43-47.
25. Wain LV, Bailes E, Bibollet-Ruche F, Decker JM, Keele BF, Van Heuverswyn F, Li Y, Takehisa J, Ngole EM, Shaw GM, Peeters M, Hahn BH, Sharp PM. 2007. Adaptation of HIV-1 to its human host. Mol. Biol. Evol. 24:1853-1860.
26. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421.
27. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. 2011. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 8:78. doi:10.1186/1742-4690-8-78.
28. Delaugerre C, De Oliveira F, Lascoux-Combe C, Plantier JC, Simon F. 2011. HIV-1 group N: travelling beyond Cameroon. Lancet 378:1894. doi:10.1016/S0140-6736(11)61457-8.
29. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, Kluge SF, Hermkes E, Moll M, Barker E, Peeters M, Learn GH, Bibollet-Ruche F, Fritz JV, Fackler OT, Hahn BH, Kirchhoff F. 2012. Human tetherin exerts strong selection pressure on the HIV-1 groupNVpu protein. PLoS Pathog. 8:e1003093. doi:10.1371/journal.ppat.1003093.
30. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. 2005. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J. Virol. 79:8979-8990.
31. Archer J, Robertson DL. 2007. Understanding the diversification of HIV-1 groups M and O. AIDS 21:1693-1700.
32. Roques P, Robertson DL, Souquiere S, Damond F, Ayouba A, Farfara I, Depienne C, Nerrienet E, Dormont D, Brun-Vezinet F, Simon F, Mauclere P. 2002. Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure. Virology 302:259-273.
33. Yamaguchi J, Vallari AS, Swanson P, Bodelle P, Kaptue L, Ngansop C, Zekeng L, Gurtler LG, Devare SG, Brennan CA. 2002. Evaluation of HIV type 1 group O isolates: identification of five phylogenetic clusters. AIDS Res. Hum. Retroviruses 18:269-282.
34. Vallari A, Bodelle P, Ngansop C, Makamche F, Ndembi N, Mbanya D, Kaptue L, Gurtler LG, McArthur CP, Devare SG, Brennan CA. 2010. Four new HIV-1 groupNisolates from Cameroon: prevalence continues to be low. AIDS Res. Hum. Retroviruses 26:109-115.
35. Roques P, Robertson DL, Souquiere S, Apetrei C, Nerrienet E, Barre- Sinoussi F, Muller-Trutwin M, Simon F. 2004. Phylogenetic characteristics of three new HIV-1 N strains and implications for the origin of group N. AIDS 18:1371-1381.
36. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. 2012. Natural SIV hosts: showing AIDS the door. Science 335:1188-1193.
37. Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, Li Y, Learn GH, Beasley TM, Schumacher-Stankey J, Wroblewski E, Mosser A, Raphael J, Kamenya S, Lonsdorf EV, Travis DA, Mlengeya T, Kinsel MJ, Else JG, Silvestri G, Goodall J, Sharp PM, Shaw GM, Pusey AE, Hahn BH. 2009. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 460:515-519.
38. Etienne L, Nerrienet E, LeBreton M, Bibila GT, Foupouapouognigni Y, Rousset D, Nana A, Djoko CF, Tamoufe U, Aghokeng AF, Mpoudi- Ngole E, Delaporte E, Peeters M, Wolfe ND, Ayouba A. 2011. Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms. Retrovirology 8:4. doi:10.1186/1742-4690-8-4.
39. Nkengasong JN, Fransen K, Willems B, Karita E, Vingerhoets J, Kestens L, Colebunders R, Piot P, van der Groen G. 1997. Virologic, immunologic, and clinical follow-up of a couple infected by the human immunodeficiency virus type one, group O. J. Med. Virol. 51:202-209.
40. Andreoletti L, Reveil B, Moret H, Brodard V, Philbert F, Tabary T, Cohen JH. 2007. Significant genetic and antigenic variability within the env gene of systemic human immunodeficiency virus type 1 group O populations during the natural course of a heterosexual infection: a pilot study. J. Clin. Microbiol. 45:1319-1321.
41. Geuenich S, Kaderali L, Allespach I, Sertel S, Keppler OT. 2009. Biological signature characteristics of primary isolates from human immunodeficiency virus type 1 group O in ex vivo human tonsil histocultures. J. Virol. 83:10494-10503.
42. Vessiere A, Rousset D, Kfutwah A, Leoz M, Depatureaux A, Simon F, Plantier JC. 2010. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J. Acquir. Immune Defic. Syndr. 53:107-110.
43. Depatureaux A, Leoz M, De Oliveira F, Gueudin M, Damond F, Descamps D, Brun-Vezinet F, Lemee V, Simon F, Barin F, Plantier JC. 19 June 2010. Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data. Med. Mal. Infect. (In French.) doi:10.1016/j.medmal.2010.1004.1011.
44. Chaix-Baudier ML, Chappey C, Burgard M, Letourneur F, Igual J, Saragosti S, Rouzioux C. 1998. First case of mother-to-infant HIV type 1 group O transmission and evolution of C2V3 sequences in the infected child. French HIV Pediatric Cohort Study Group. AIDS Res. Hum. Retroviruses 14:15-23.
45. Gueudin M, Lemee V, Ferre V, Beby-Defaux A, Pathe JP, Guist'hau O, Braun J, Simon F, Plantier JC. 2004. Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O. J. Acquir. Immune Defic. Syndr. 36:639-641.
46. Ayouba A, Souquieres S, Njinku B, Martin PM, Muller-Trutwin MC, Roques P, Barre-Sinoussi F, Mauclere P, Simon F, Nerrienet E. 2000. HIV-1 group N among HIV-1-seropositive individuals in Cameroon. AIDS 14:2623-2625.
47. Yamaguchi J, Coffey R, Vallari A, Ngansop C, Mbanya D, Ndembi N, Kaptue L, Gurtler LG, Bodelle P, Schochetman G, Devare SG, Brennan CA. 2006. Identification of HIV type 1 group N infections in a husband and wife in Cameroon: viral genome sequences provide evidence for horizontal transmission. AIDS Res. Hum. Retroviruses 22:83-92.
48. Yamaguchi J, McArthur CP, Vallari A, Coffey R, Bodelle P, Beyeme M, Schochetman G, Devare SG, Brennan CA. 2006. HIV-1 group N: evidence of ongoing transmission in Cameroon. AIDS Res. Hum. Retroviruses 22:453-457.
49. Delaporte E, Janssens W, Peeters M, Buve A, Dibanga G, Perret JL, Ditsambou V, Mba JR, Courbot MC, Georges A, Bourgeois A, Samb B, Henzel D, Heyndrickx L, Fransen K, van der Groen G, Larouze B. 1996. Epidemiological and molecular characteristics of HIV infection in Gabon, 1986-1994. AIDS 10:903-910.
50. Zekeng L, Obiang Sima J, Hampl H, Ndemesogo JM, Ntutumu J, Sima V, Devare S, Kaptue L, Gurtler L. 1997. Update on HIV-1 group O infection in Equatorial Guinea, Central Africa. AIDS 11:1410-1412.
51. Hunt JC, Brennan CA, Golden AM, Yamaguchi J, Lund JK, Vallari AS, Hickman RK, Zekeng L, Gurtler LG, Hampl H, Kaptue L, Devare SG. 1997. Molecular analyses of HIV-1 group O and HIV-2 variants from Africa. Leukemia 11(Suppl 3):138-141.
52. Bibollet-Ruche F, Peeters M, Mboup S, Ekaza E, Gandji R, Torimiro J, Mpoudi EN, Amblard J, Dibanga G, Saidou M, Esu-Williams E, Vanden Haesevelde M, Saman E, Delaporte E. 1998. Molecular characterization of the envelope transmembrane glycoprotein of 13 new human immunodeficiency virus type 1 group O strains from six different African countries. AIDS Res. Hum. Retroviruses 14:1281-1285.
53. Ayouba A, Mauclere P, Martin PM, Cunin P, Mfoupouendoun J, Njinku B, Souquieres S, Simon F. 2001. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg. Infect. Dis. 7:466-467.
54. Vergne L, Bourgeois A, Mpoudi-Ngole E, Mougnutou R, Mbuagbaw J, Liegeois F, Laurent C, Butel C, Zekeng L, Delaporte E, Peeters M. 2003. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology 310:254-266.
55. Takehisa J, Zekeng L, Ido E, Yamaguchi-Kabata Y, Mboudjeka I, Harada Y, Miura T, Kaptue L, Hayami M. 1999. Human immunodeficiency virus type 1 intergroup (M/O) recombination in Cameroon. J. Virol. 73:6810-6820.
56. Peeters M, Liegeois F, Torimiro N, Bourgeois A, Mpoudi E, Vergne L, Saman E, Delaporte E, Saragosti S. 1999. Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. J. Virol. 73:7368-7375.
57. Yamaguchi BP, Vallari AS, Coffey R, McArthur CP, Schochetman G, Devare SG, Brennan CA. 2004. HIV infections in northwestern Cameroon: identification of HIV type 1 groupOand dual HIV type 1 groupM and group O infections. AIDS Res. Hum. Retroviruses 20:944-955.
58. Vessiere A, De Oliveira F, Leoz M, Rousset D, Kfutwah A, Simon F, Plantier JC. 2011. HIV-1 M/O dual infections and recombinant forms circulating in Cameroon and France, abstr 461. Abstr. 18th Conf. Retroviruses Opportun. Infect., Boston, MA.
59. Kabeya CM, Esu-Williams E, Eni E, Peeters M, Saman E, Delaporte E. 1995. Evidence for HIV-1 group O infection in Nigeria. Lancet 346:308.
60. Songok EM, Libondo DK, Rotich MC, Oogo SA, Tukei PM. 1996. Surveillance for HIV-1 subtypes O and M in Kenya. Lancet 347:1700.
61. Heyndrickx L, Alary M, Janssens W, Davo N, van der Groen G. 1996. HIV-1 group O and group M dual infection in Benin. Lancet 347:902-903.
62. Peeters M, Gaye A, Mboup S, Badombena W, Bassabi K, Prince-David M, Develoux M, Liegeois F, van der Groen G, Saman E, Delaporte E. 1996. Presence of HIV-1 groupOinfection in West Africa. AIDS 10:343-344.
63. Peeters M, Gueye A, Mboup S, Bibollet-Ruche F, Ekaza E, Mulanga C, Ouedrago R, Gandji R, Mpele P, Dibanga G, Koumare B, Saidou M, Esu-Williams E, Lombart JP, Badombena W, Luo N, Vanden Hae-Sevelde M, Delaporte E. 1997. Geographical distribution of HIV-1 group O viruses in Africa. AIDS 11:493-498.
64. Nkengasong J, Sylla-Koko F, Peeters M, Ellenberger D, Sassan- Morokro M, Ekpini RA, Msellati P, Greenberg AE, Combe P, Rayfield M. 1998. HIV-1 group O virus infection in Abidjan, Cote d'Ivoire. AIDS 12:1565-1566.
65. Hampl H, Sawitzky D, Stoffler-Meilicke M, Groh A, Schmitt M, Eberle J, Gurtler L. 1995. First case of HIV-1 subtype 0 infection in Germany. Infection 23:369-370.
66. Rayfield MA, Sullivan P, Bandea CI, Britvan L, Otten RA, Pau CP, Pieniazek D, Subbarao S, Simon P, Schable CA, Wright AC, Ward J, Schochetman G. 1996. HIV-1 group O virus identified for the first time in the United States. Emerg. Infect. Dis. 2:209-212.
67. Soriano V, Gutierrez M, Garcia-Lerma G, Aguilera O, Mas A, Bravo R, Perez-Labad ML, Baquero M, Gonzalez-Lahoz J. 1996. First case of HIV-1 group O infection in Spain. Vox Sang. 71:66.
68. Gould K. 1997. Infection with HIV-1 group O. AIDS Patient Care STDs 11:399-405.
69. Sullivan PS, Do AN, Ellenberger D, Pau CP, Paul S, Robbins K, Kalish M, Storck C, Schable CA, Wise H, Tetteh C, Jones JL, McFarland J, Yang C, Lal RB, Ward JW. 2000. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States. J. Infect. Dis. 181:463-469.
70. Barin F, Cazein F, Lot F, Pillonel J, Brunet S, Thierry D, Damond F, Brun-Vezinet F, Desenclos JC, Semaille C. 2007. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 21:2351-2353.
71. Agut H, Rabanel B, Candotti D, Huraux JM, Remy G, Tabary T, Ingrand D, Chippaux C, Chamaret S, Dauguet C, Guetard D, Montagnier L. 1992. Isolation of atypical HIV-1-related retrovirus from AIDS patient. Lancet 340:681-682.
72. Brand D, Beby-Defaux A, Mace M, Brunet S, Moreau A, Godet C, Jais X, Cazein F, Semaille C, Barin F. 2004. First identification of HIV-1 groups M and O dual infections in Europe. AIDS 18:2425-2428.
73. Plantier JC, Lemee V, Dorval I, Gueudin M, Braun J, Hutin P, Ruffault A, Simon F. 2004. HIV-1 group M superinfection in an HIV-1 group O-infected patient. AIDS 18:2444-2446.
74. Vessiere A, Leoz M, Brodard V, Strady C, Lemee V, Depatureaux A, Simon F, Plantier JC. 2010. First evidence of a HIV-1 M/O recombinant form circulating outside Cameroon. AIDS 24:1079-1082.
75. Loussert-Ajaka I, Ly TD, Chaix ML, Ingrand D, Saragosti S, Courouce AM, Brun-Vezinet F, Simon F. 1994. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 343:1393-1394.
76. Simon F, Ly TD, Baillou-Beaufils A, Fauveau V, De Saint-Martin J, Loussert-Ajaka I, Chaix ML, Saragosti S, Courouce AM, Ingrand D, Janot C, Brun-Vézinet F. 1994. Sensitivity of screening kits for anti- HIV-1 subtype O antibodies. AIDS 8:1628-1629.
77. Ly TD, Laperche S, Brennan C, Vallari A, Ebel A, Hunt J, Martin L, Daghfal D, Schochetman G, Devare S. 2004. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J. Virol. Methods 122:185-194.
78. Zouhair S, Roussin-Bretagne S, Moreau A, Brunet S, Laperche S, Maniez M, Barin F, Harzic M. 2006. Group O human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays. J. Clin. Microbiol. 44:662-665.
79. Henquell C, Jacomet C, Antoniotti O, Chaib A, Regagnon C, Brunet S, Peigue-Lafeuille H, Barin F. 2008. Difficulties in diagnosing group O human immunodeficiency virus type 1 acute primary infection. J. Clin. Microbiol. 46:2453-2456.
80. Gautheret-Dejean A, Mesmin-Poho S, Birguel J, Lemee V, Huraux JM, Plantier JC. 2008. Unequal detection of HIV type 1 group O infection by simple rapid tests. Clin. Infect. Dis. 46:1936-1937.
81. Plantier JC, Djemai M, Lemee V, Reggiani A, Leoz M, Burc L, Vessiere A, Rousset D, Poveda JD, Henquell C, Gautheret-Dejean A, Barin F. 2009. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J. Clin. Microbiol. 47:2906-2911.
82. Aghokeng AF, Mpoudi-Ngole E, Dimodi H, Atem-Tambe A, Tongo M, Butel C, Delaporte E, Peeters M. 2009. Inaccurate diagnosis of HIV-1 groupMand O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One 4:e7702. doi:10.1371/journal.pone.0007702.
83. Laperche S, Leballais L, Ly TD, Plantier JC. 2012. Failures in the detection of HIV p24 antigen with the Determine HIV-1/2 Ag/Ab Combo rapid test. J. Infect. Dis. 206:1946-1947.
84. Ly TD, Plantier JC, Leballais L, Gonzalo S, Lemee V, Laperche S. 2012. The variable sensitivity of HIV Ag/Ab combination assays in the detection of p24Ag according to genotype could compromise the diagnosis of early HIV infection. J. Clin. Virol. 55:121-127.
85. Simon F, Souquiere S, Damond F, Kfutwah A, Makuwa M, Leroy E, Rouquet P, Berthier JL, Rigoulet J, Lecu A, Telfer PT, Pandrea I, Plantier JC, Barre-Sinoussi F, Roques P, Muller-Trutwin MC, Apetrei C. 2001. Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res. Hum. Retroviruses 17:937-952.
86. Barin F, Plantier JC, Brand D, Brunet S, Moreau A, Liandier B, Thierry D, Cazein F, Lot F, Semaille C, Desenclos JC. 2006. Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic. J. Med. Virol. 78(Suppl 1):S13-S18. doi:10.1002/jmv.20600.
87. Plantier JC, Gueudin M, Damond F, Braun J, Mauclere P, Simon F. 2003. Plasma RNA quantification and HIV-1 divergent strains. J. Acquir. Immune Defic. Syndr. 33:1-7.
88. Swanson P, de Mendoza C, Joshi Y, Golden A, Hodinka RL, Soriano V, Devare SG, Hackett J, Jr. 2005. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J. Clin. Microbiol. 43:3860-3868.
89. Gueudin M, Plantier JC, Lemee V, Schmitt MP, Chartier L, Bourlet T, Ruffault A, Damond F, Vray M, Simon F. 2007. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 44:500-505.
90. Gueudin M, Plantier JC, Damond F, Roques P, Mauclere P, Simon F. 2003. Plasma viral RNA assay in HIV-1 group O infection by real-time PCR. J. Virol. Methods 113:43-49.
91. Gueudin M, Leoz M, Lemee V, De Oliveira F, Vessiere A, Kfutwah A, Plantier JC. 2012. A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection. J. Clin. Microbiol. 50:831-836.
92. Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C. 2010. Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J. Clin. Microbiol. 48:1413-1416.
93. Sire JM, Vray M, Merzouk M, Plantier JC, Pavie J, Maylin S, Timsit J, Lascoux-Combe C, Molina JM, Simon F, Delaugerre C. 2011. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott realtime HIV-1 PCR assays. J. Acquir. Immune Defic. Syndr. 56:239-243.
94. Tang N, Huang S, Salituro J, Mak WB, Cloherty G, Johanson J, Li YH, Schneider G, Robinson J, Hackett J, Jr, Swanson P, Abravaya K. 2007. A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse groupMsubtypes A-H, groupOand groupN samples. J. Virol. Methods 146:236-245.
95. Depatureaux A, Charpentier C, Leoz M, Unal G, Damond F, Kfutwah A, Vessiere A, Simon F, Plantier JC. 2011. Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J. Acquir. Immune Defic. Syndr. 56:139-145.
96. Depatureaux A, Leoz M, Vessière A, Rousset D, Damond F, Simon F, Plantier JC. 2009. Natural presence of resistance mutation Y181C in HIV-1 group O variants is clade-dependent, p A93. In XVIII International HIV Drug Resistance Workshop: basic principles & clinical implications, vol 14, suppl 1. Antiviral Therapy, Fort Myers, FL.
97. Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenroder O, Krausslich HG, Arts EJ. 2010. Divergent evolution in reverse transcriptase (RT) of HIV-1 group O andMlineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J. Virol. 84:9817-9830.
98. Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Loussert- Ajaka I, Simon F, Saragosti S, Brun-Vezinet F. 1997. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J. Virol. 71:8893-8898.
99. Tuaillon E, Gueudin M, Lemee V, Gueit I, Roques P, Corrigan GE, Plantier JC, Simon F, Braun J. 2004. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J. Acquir. Immune Defic. Syndr. 37:1543-1549.
100. Luk KC, Kaptue L, Zekeng L, Soriano V, Gurtler L, Devare SG, Schochetman G, Hackett J, Jr. 2001. Naturally occurring sequence polymorphisms within HIV type 1 group O protease. AIDS Res. Hum. Retroviruses 17:1555-1561.
101. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:57-65.
102. Parkin NT, Schapiro JM. 2004. Antiretroviral drug resistance in nonsubtype B HIV-1, HIV-2 and SIV. Antivir. Ther. 9:3-12.
103. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, Campa P, Matheron S, Chene G, Brun-Vezinet F, Descamps D. 2008. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob. Agents Chemother. 52:1545-1548.
104. Leoz M, Depatureaux A, Vessiere A, Roquebert B, Damond F, Rousset D, Roques P, Simon F, Plantier JC. 2008. Integrase polymorphism and HIV-1 group O diversity. AIDS 22(10):1239-1243.
105. Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, Soriano V. 2009. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res. Hum. Retroviruses 25:225-227.
106. Depatureaux A, Leoz M, Le Moal G, Pathe JP, Pavie J, Batisse D, Daneluzzi V, Genet P, Gerard L, Lascaux-Cametz AS, Lambolez T, Chennebault JM, Plantier JC. 2012. Raltegravir-based regimens are effective in HIV-1 group O-infected patients. J. Acquir. Immune Defic. Syndr. 61:e1-e3. doi:10.1097/QAI.0b013e31826327c4.
107. Aghokeng AF, Kouanfack C, Peeters M, Mpoudi-Ngole E, Delaporte E. 2013. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon. AIDS Res. Hum. Retroviruses 29:1-3.
108. Depatureaux A, Charpentier C, Collin G, Leoz M, Descamps D, Vessiere A, Damond F, Rousset D, Brun-Vezinet F, Plantier JC. 2010. Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. Antimicrob. Agents Chemother. 54:4016-4019.
109. Chinnadurai R, Munch J, Dittmar MT, Kirchhoff F. 2005. Inhibition of HIV-1 groupMandOisolates by fusion inhibitors. AIDS 19:1919-1922.
110. Poveda E, Barreiro P, Rodes B, Soriano V. 2005. Enfuvirtide is active against HIV type 1 group O. AIDS Res. Hum. Retroviruses 21:583-585.
111. Rupp D, Geuenich S, Keppler OT. 2010. Poor performance of bioinformatics programs for genotypic prediction of coreceptor usage of HIV-1 group O isolates. J. Acquir. Immune Defic. Syndr. 53:412-413.
112. de Baar MP, Janssens W, de Ronde A, Fransen K, Colebunders R, Kestens L, van der Groen G, Goudsmit J. 2000. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. AIDS Res. Hum. Retroviruses 16:1385-1394.
113. Rodes B, de Mendoza C, Rodgers M, Newell A, Jimenez V, Lopez- Brugada RM, Soriano V. 2005. Treatment response and drug resistance in patients infected with HIV type 1 group O viruses. AIDS Res. Hum. Retroviruses 21:602-607.
114. Pieniazek D, Ziebell R, Ocfemia CB, Saduvala N, Kline R, Prejean J, Kim D, Hall I. 2012. Phylogenetic surveillance of HIV-1 non-B subtypes among US-born and foreign-born individuals living in the US revealed similar viral genetic diversity but different race and male transmission patterns, abstr 515. Abstr. 19th Conf. Retroviruses Opportun. Infect., Seattle, WA.